(RTTNews) - ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company focused on allergic reaction therapies, announced on Tuesday its participation in the 2025 American Academy of Allergy, Asthma, and Immunology or AAAAI Annual Meeting, scheduled for February 28 to March 3 in San Diego, California.
During the meeting, ARS Pharmaceuticals will present nine studies showcasing the safety and efficacy of neffy or epinephrine nasal spray, the first FDA-approved needle-free treatment for Type I allergic reactions and anaphylaxis in patients weighing 30 kg or greater.
Data will include pharmacokinetic and pharmacodynamic analysis, efficacy comparisons with intramuscular auto-injectors, and insights into the treatment of allergic rhinitis and anaphylaxis under various conditions.
Notably, an oral presentation will highlight the superior efficacy of neffy compared to intramuscular auto-injectors in an oral food challenge setting, while additional poster presentations will explore its use in different populations, including children and patients with allergic conditions requiring emergency epinephrine.
Sarina Tanimoto, MD, PhD, Chief Medical Officer of ARS Pharmaceuticals, emphasized that the findings will further validate the potential of neffy as a more accessible and effective treatment option for managing severe allergic reactions.
Currently, SPRY is trading at $12.18 up by 1.08%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
